Achelois BioPharma

Achelois BioPharma is an early-stage biotech pioneering a novel, patient-specific approach to T-cell therapy. By using a patient's own tumor cells to 'train' their T-cells, the company bypasses the lengthy process of identifying specific tumor antigens or engineering synthetic receptors. This platform has the potential to generate highly personalized, polyclonal T-cell products that may address tumor heterogeneity and immune evasion more effectively than off-the-shelf or single-target approaches. Founded in 2020 and based in San Diego, the company is positioned in the rapidly evolving field of cellular immunotherapy.

A platform for creating personalized autologous T-cell therapies by 'training' a patient's own T-cells ex vivo using their tumor cells, aiming to generate a polyclonal, tumor-specific immune response without genetic engineering or prior target discovery.

Achelois competes in the crowded cell therapy for solid tumors space, facing companies using engineered CAR-T, TCR-T, TIL, and NK cell approaches. Its key differentiator is the avoidance of genetic engineering and predefined targets. However, it must prove its approach can match or exceed the potency of engineered cells while solving the logistical hurdles of personalized manufacturing.